Russell E Ware

List of Publications by Year
in descending order

247 papers	12,463 citations	38742 50 h-index	27406 106 g-index
253 all docs	253 docs citations	253 times ranked	7455 citing authors

#	Article	IF	Citations
1	Management of Sickle Cell Disease. JAMA - Journal of the American Medical Association, 2014, 312, 1033.	7.4	1,189
2	Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease. New England Journal of Medicine, 2000, 342, 1855-1865.	27.0	1,062
3	Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet, The, 2011, 377, 1663-1672.	13.7	647
4	Sickle cell disease. Lancet, The, 2017, 390, 311-323.	13.7	639
5	A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. New England Journal of Medicine, 2019, 381, 509-519.	27.0	401
6	Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemiaâ€"TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet, The, 2016, 387, 661-670.	13.7	375
7	How I use hydroxyurea to treat young patients with sickle cell anemia. Blood, 2010, 115, 5300-5311.	1.4	325
8	R2* magnetic resonance imaging of the liver in patients with iron overload. Blood, 2009, 113, 4853-4855.	1.4	311
9	Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood, 2012, 119, 3925-3932.	1.4	308
10	Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood, 2004, 103, 2039-2045.	1.4	306
11	Silent cerebral infarcts: a review on a prevalent and progressive cause of neurologic injury in sickle cell anemia. Blood, 2012, 119, 4587-4596.	1.4	262
12	Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood, 2005, 106, 2269-2275.	1.4	251
13	Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood, 2012, 120, 4304-4310.	1.4	204
14	Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa. New England Journal of Medicine, 2019, 380, 121-131.	27.0	200
15	Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood, 2007, 110, 1043-1047.	1.4	192
16	Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood, 2010, 116, 687-692.	1.4	187
17	Hydroxyurea therapy for sickle cell anemia. Expert Opinion on Drug Safety, 2015, 14, 1749-1758.	2.4	172
18	Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. Journal of Pediatrics, 2004, 145, 346-352.	1.8	168

#	Article	IF	Citations
19	A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. Journal of Pediatrics, 2001, 139, 790-796.	1.8	165
20	Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood, 2002, 99, 10-14.	1.4	154
21	Hydroxyurea as an Alternative to Blood Transfusions for the Prevention of Recurrent Stroke in Children With Sickle Cell Disease. Blood, 1999, 94, 3022-3026.	1.4	148
22	Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood, 2011, 118, 4985-4991.	1.4	139
23	Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?. Current Opinion in Hematology, 2011, 18, 158-165.	2.5	131
24	Long-Term Outcome and Evaluation of Organ Function in Pediatric Patients Undergoing Haploidentical and Matched Related Hematopoietic Cell Transplantation for Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2013, 19, 820-830.	2.0	127
25	Genetic predictors for stroke in children with sickle cell anemia. Blood, 2011, 117, 6681-6684.	1.4	119
26	Burden of sickle cell trait and disease in the Uganda Sickle Surveillance Study (US3): a cross-sectional study. The Lancet Global Health, 2016, 4, e195-e200.	6.3	116
27	Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood, 2000, 95, 3589-3593.	1.4	114
28	Renal Function in Infants with Sickle Cell Anemia: Baseline Data from the BABY HUG Trial. Journal of Pediatrics, 2010, 156, 66-70.e1.	1.8	109
29	Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia. Blood, 2017, 130, 2585-2593.	1.4	101
30	Advances in the use of hydroxyurea. Hematology American Society of Hematology Education Program, 2009, 2009, 62-69.	2.5	100
31	Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatric Blood and Cancer, 2005, 45, 982-985.	1.5	93
32	A prospective newborn screening and treatment program for sickle cell anemia in Luanda, Angola. American Journal of Hematology, 2013, 88, 984-989.	4.1	89
33	Malignancy in patients with sickle cell disease. American Journal of Hematology, 2003, 74, 249-253.	4.1	88
34	Development and evaluation of iManage: A selfâ€management app coâ€designed by adolescents with sickle cell disease. Pediatric Blood and Cancer, 2017, 64, 139-145.	1.5	84
35	A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatric Blood and Cancer, 2009, 52, 609-615.	1.5	82
36	Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatric Blood and Cancer, 2008, 50, 293-297.	1.5	81

#	Article	IF	Citations
37	Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial. Blood, 2014, 124, 891-898.	1.4	75
38	Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. New England Journal of Medicine, 2020, 382, 2524-2533.	27.0	72
39	Sickle cell anemia in sub-Saharan Africa: advancing the clinical paradigm through partnerships and research. Blood, 2017, 129, 155-161.	1.4	70
40	Inherited DNA mutations contributing to thrombotic complications in patients with Sickle cell disease. , 1998, 59, 267-272.		69
41	Quantitative Analysis of Howell-Jolly Bodies in Children with Sickle Cell Disease. Experimental Hematology, 2007, 35, 179-183.	0.4	66
42	Stroke with transfusions changing to hydroxyurea (SWiTCH): A phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatric Blood and Cancer, 2011, 57, 1011-1017.	1.5	66
43	A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. American Journal of Hematology, 2017, 92, 1333-1339.	4.1	66
44	Whole-exome sequencing for RH genotyping and alloimmunization risk in children with sickle cell anemia. Blood Advances, 2017, 1, 1414-1422.	5.2	64
45	Hydroxyurea for Children with Sickle Cell Disease. Pediatric Clinics of North America, 2008, 55, 483-501.	1.8	59
46	Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood, 2013, 121, 3237-3245.	1.4	59
47	From Infancy to Adolescence. Medicine (United States), 2014, 93, e215.	1.0	59
48	Prevention of conversion to abnormal transcranial <scp>D</scp>oppler with hydroxyurea in sickle cell anemia: A <scp>P</scp>hase III international randomized clinical trial. American Journal of Hematology, 2015, 90, 1099-1105.	4.1	59
49	Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Haematologica, 2010, 95, 1599-1603.	3.5	55
50	Effects of hydroxyurea treatment for patients with hemoglobin <scp>SC</scp> disease. American Journal of Hematology, 2016, 91, 238-242.	4.1	54
51	Is Sickle Cell Anemia a Neglected Tropical Disease?. PLoS Neglected Tropical Diseases, 2013, 7, e2120.	3.0	53
52	The pediatric hydroxyurea phase III clinical trial (BABY HUG): Challenges of study design. Pediatric Blood and Cancer, 2010, 54, 250-255.	1.5	51
53	Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2010, 698, 38-42.	1.7	51
54	Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. American Journal of Hematology, 2019, 94, 871-879.	4.1	51

#	Article	IF	Citations
55	The natural history of conditional transcranial Doppler flow velocities in children with sickle cell anaemia. British Journal of Haematology, 2008, 142, 94-99.	2.5	50
56	Quantitative analysis of erythrocytes containing fetal hemoglobin (F cells) in children with sickle cell disease. , 1997, 54, 40-46.		49
57	Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the <scp>TW</scp>i<scp>TCH</scp> trial. British Journal of Haematology, 2016, 172, 122-130.	2.5	47
58	Oligoclonal expansion of CD45RO+ T lymphocytes in Omenn syndrome. Journal of Clinical Immunology, 1997, 17, 322-332.	3.8	44
59	Do the acute platelet responses of patients with immune thrombocytopenic purpura (ITP) to IV antiâ€Ð and to IV gammaglobulin predict response to subsequent splenectomy?. American Journal of Hematology, 2001, 67, 27-33.	4.1	44
60	Characteristics of a rapid, pointâ€ofâ€care lateral flow immunoassay for the diagnosis of sickle cell disease. American Journal of Hematology, 2016, 91, 205-210.	4.1	44
61	Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: Results from the BABYâ€HUG phase III clinical trial. Pediatric Blood and Cancer, 2012, 59, 254-257.	1.5	42
62	Hydroxyurea: An alternative to transfusion therapy for stroke in sickle cell anemia. American Journal of Hematology, 1995, 50, 140-143.	4.1	41
63	A Cost-Effectiveness Analysis of a Pilot Neonatal Screening Program forÂSickle Cell Anemia in the Republic of Angola. Journal of Pediatrics, 2015, 167, 1314-1319.	1.8	41
64	Hydroxyurea Therapy for Children With Sickle Cell Anemia in Subâ€Saharan Africa: Rationale and Design of the REACH Trial. Pediatric Blood and Cancer, 2016, 63, 98-104.	1.5	41
65	Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities. American Journal of Hematology, 2012, 87, 428-430.	4.1	38
66	Chemical and Functional Analysis of Hydroxyurea Oral Solutions. Journal of Pediatric Hematology/Oncology, 2004, 26, 179-184.	0.6	37
67	Immunologic Effects of Hydroxyurea in Sickle Cell Anemia. Pediatrics, 2014, 134, 686-695.	2.1	37
68	Optimizing hydroxyurea therapy for sickle cell anemia. Hematology American Society of Hematology Education Program, 2015, 2015, 436-443.	2.5	37
69	Evidence gaps in the management of sickle cell disease: A summary of needed research. American Journal of Hematology, 2015, 90, 273-275.	4.1	37
70	Development of a pharmacokineticâ€guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. British Journal of Clinical Pharmacology, 2016, 81, 742-752.	2.4	35
71	Childhood hepatic mesenchymoma: Successful treatment with surgery and multiple-agent chemotherapy. Medical and Pediatric Oncology, 1988, 16, 62-65.	1.0	34
72	Effective use of hydroxyurea for sickle cell anemia in low-resource countries. Current Opinion in Hematology, 2020, 27, 172-180.	2.5	34

#	Article	IF	Citations
73	Hemoglobin S/OARAB: Thirteen new cases and review of the literature. , 1999, 60, 279-284.		32
74	Empowering newborn screening programs in African countries through establishment of an international collaborative effort. Journal of Community Genetics, 2020, 11, 253-268.	1.2	32
75	Stable-Isotope Dilution HPLCâ€“Electrospray Ionization Tandem Mass Spectrometry Method for Quantifying Hydroxyurea in Dried Blood Samples. Clinical Chemistry, 2016, 62, 1593-1601.	3.2	31
76	Phenotypic and functional analysis of lymphocytes in paroxysmal nocturnal hemoglobinuria. American Journal of Hematology, 1995, 50, 244-253.	4.1	30
77	Pilot of the Chronic Disease Self-Management Program for Adolescents and Young Adults With Sickle Cell Disease. Journal of Adolescent Health, 2017, 60, 120-123.	2.5	30
78	Simultaneous point-of-care detection of anemia and sickle cell disease in Tanzania: the RAPID study. Annals of Hematology, 2018, 97, 239-246.	1.8	29
79	Whole Exome Sequencing Identifies Novel Genes for Fetal Hemoglobin Response to Hydroxyurea in Children with Sickle Cell Anemia. PLoS ONE, 2014, 9, e110740.	2.5	28
80	Elevated levels of tumor necrosis factor-beta, gamma-interferon, and IL-6 mRNA in Castleman's disease. , 1996, 26, 48-53.		26
81	Identification and characterization of an inherited mutation of PIG-A in a patient with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology, 1996, 93, 590-593.	2.5	26
82	Detection of hemoglobin variants in erythrocytes by flow cytometry. , 1999, 35, 242-248.		26
83	Hydroxycarbamide treatment and brain MRI/MRA findings in children with sickle cell anaemia. British Journal of Haematology, 2016, 175, 331-338.	2.5	26
84	Prevalence of inherited blood disorders and associations with malaria and anemia in Malawian children. Blood Advances, 2018, 2, 3035-3044.	5.2	25
85	Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia. PLoS ONE, 2016, 11, e0164364.	2.5	25
86	Chromosome damage and repair in children with sickle cell anaemia and longâ€term hydroxycarbamide exposure. British Journal of Haematology, 2011, 154, 134-140.	2.5	24
87	Longâ€term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. American Journal of Hematology, 2011, 86, 357-361.	4.1	24
88	Translating sickle cell guidelines into practice for primary care providers with Project ECHO. Medical Education Online, 2016, 21, 33616.	2.6	23
89	Absence of hydroxyureaâ€induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia. British Journal of Haematology, 2021, 194, 252-266.	2.5	23
90	Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease. British Journal of Haematology, 2021, 194, 970-979.	2.5	22

#	Article	IF	Citations
91	Liver iron concentration measurements by MRI in chronically transfused children with sickle cell anemia: baseline results from the TWiTCH trial. American Journal of Hematology, 2015, 90, 806-810.	4.1	21
92	Towards a point-of-care strip test to diagnose sickle cell anemia. PLoS ONE, 2017, 12, e0177732.	2.5	21
93	Hydroxyurea to lower transcranial Doppler velocities and prevent primary stroke: the Uganda NOHARM sickle cell anemia cohort. Haematologica, 2020, 105, e272-e275.	3.5	21
94	Novel Use of Hydroxyurea in an African Region With Malaria: Protocol for a Randomized Controlled Clinical Trial. JMIR Research Protocols, 2016, 5, e110.	1.0	21
95	A Pilot Study of Epigenetic-Differentiation Therapy with Decitabine to Treat Î²-Thalassemia Intermedia. Blood, 2010, 116, 2078-2078.	1.4	21
96	Hydroxyurea therapy for management of secondary erythrocytosis in cyanotic congenital heart disease. American Journal of Hematology, 2007, 82, 740-743.	4.1	20
97	Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Subâ€Saharan Africa. American Journal of Hematology, 2018, 93, 537-545.	4.1	20
98	Optimizing hydroxyurea therapy for sickle cell anemia. Hematology American Society of Hematology Education Program, 2015, 2015, 436-443.	2.5	20
99	Original Research: Sickle cell anemia and pediatric strokes: Computational fluid dynamics analysis in the middle cerebral artery. Experimental Biology and Medicine, 2016, 241, 755-765.	2.4	19
100	TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell Anemia. Blood, 2015, 126, 3-3.	1.4	19
101	Transient erythroblastopenia in the first year of life. American Journal of Hematology, 1991, 37, 156-158.	4.1	18
102	Immunologic effects of anti-D (WinRho-SD) in children with immune thrombocytopenic purpura. , 1998, 57, 131-138.		18
103	Hydroxyurea: Analytical techniques and quantitative analysis. Blood Cells, Molecules, and Diseases, 2017, 67, 135-142.	1.4	18
104	Hydroxyurea for children with sickle cell anemia: Prescribe it early and often. Pediatric Blood and Cancer, 2019, 66, e27778.	1.5	18
105	Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload. British Journal of Haematology, 2015, 169, 262-266.	2.5	17
106	Hemoglobin sickle-lepore: Report of two siblings and review of the literature. American Journal of Hematology, 1993, 44, 192-195.	4.1	16
107	Shared decision making for hydroxyurea treatment initiation in children with sickle cell anemia. Pediatric Blood and Cancer, 2015, 62, 184-185.	1.5	16
108	Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokineticsâ€guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. British Journal of Haematology, 2021, 194, 617-625.	2.5	16

#	Article	IF	Citations
109	An accurate and inexpensive colorâ€based assay for detecting severe anemia in a limitedâ€resource setting. American Journal of Hematology, 2015, 90, 1122-1127.	4.1	15
110	Different clinical characteristics of paroxysmal nocturnal hemoglobinuria in pediatric and adult patients. Haematologica, 2017, 102, e76-e79.	3.5	15
111	Transcranial Doppler velocity among Jamaican children with sickle cell anaemia: determining the significance of haematological values and nutrition. British Journal of Haematology, 2018, 181, 242-251.	2.5	14
112	Urticarial vasculitis: An autoimmune disorder following therapy for Hodgkin's disease. Medical and Pediatric Oncology, 1995, 25, 208-212.	1.0	13
113	Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatric Blood and Cancer, 2012, 59, 170-172.	1.5	13
114	Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults. Pediatric Blood and Cancer, 2018, 65, e27260.	1.5	13
115	Decreased parasite burden and altered host response in children with sickle cell anemia and severe anemia with malaria. Blood Advances, 2021, 5, 4710-4720.	5.2	13
116	Familial erythrophagocytic lymphohistiocytosis: Late relapse despite continuous high-dose VP-16 chemotherapy. Medical and Pediatric Oncology, 1990, 18, 27-29.	1.0	12
117	Clinical Features of Î²-Thalassemia and Sickle Cell Disease. Advances in Experimental Medicine and Biology, 2017, 1013, 1-26.	1.6	12
118	Sickle cell screening in Uganda: High burden, human immunodeficiency virus comorbidity, and genetic modifiers. Pediatric Blood and Cancer, 2019, 66, e27807.	1.5	12
119	Increased Erythrocyte Rigidity Is Sufficient to Cause Endothelial Dysfunction in Sickle Cell Disease. Blood, 2012, 120, 818-818.	1.4	12
120	Surveillance for sickle cell disease, United Republic of Tanzania. Bulletin of the World Health Organization, 2020, 98, 859-868.	3.3	12
121	Sickle cell disease: Translating clinical care to low-resource countries through international research collaborations. Seminars in Hematology, 2018, 55, 102-112.	3.4	11
122	Development of a Hydroxyurea Decision Aid for Parents of Children With Sickle Cell Anemia. Journal of Pediatric Hematology/Oncology, 2019, 41, 56-63.	0.6	11
123	Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS). Journal of Pediatrics, 2020, 222, 236-239.	1.8	11
124	Sickle cell screening in Europe: the time has come. British Journal of Haematology, 2018, 183, 534-535.	2.5	10
125	Trends in sickle cell trait and disease screening in the Republic of Uganda, 2014â€“2019. Tropical Medicine and International Health, 2021, 26, 23-32.	2.3	10
126	Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial. British Journal of Haematology, 2021, 195, 612-620.	2.5	10

#	Article	IF	Citations
127	Stroke with Transfusions Changing to Hydroxyurea (SWiTCH): A Phase 3 Randomized Clinical Trial for Treatment of Children with Sickle Cell Anemia, Previous Stroke, and Iron Overload. Blood, 2010, 116, 844-844.	1.4	10
128	Pharmacokinetics-Guided Dosing of Hydroxyurea Can Achieve Near-Pancellular Fetal Hemoglobin Expression in Sickle Cell Anemia: F-Cell Analysis As a Benchmark for Disease-Modifying Therapy. Blood, 2019, 134, 892-892.	1.4	10
129	Elevated tricuspid regurgitation velocity in congenital hemolytic anemias: Prevalence and laboratory correlates. Pediatric Blood and Cancer, 2019, 66, e27717.	1.5	9
130	EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia. JMIR Research Protocols, 2016, 5, e185.	1.0	9
131	Children with sickle cell disease migrating to the United States from subâ€Saharan Africa. Pediatric Blood and Cancer, 2018, 65, e27000.	1.5	8
132	Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. JMIR Research Protocols, 2021, 10, e27650.	1.0	8
133	Hydroxyurea Reduces Conversion From Conditional to Abnormal TCD Velocities In Children with Sickle Cell Anemia (SCA). Blood, 2010, 116, 270-270.	1.4	8
134	Electrochemical Determination of Hydroxyurea in a Complex Biological Matrix Using MoS2-Modified Electrodes and Chemometrics. Biomedicines, 2021, 9, 6.	3.2	8
135	Tumor necrosis factor-Î± suppresses hematopoiesis in children with myelodysplasia. , 1997, 28, 69-74.		7
136	Hemoglobin variants identified in the Uganda Sickle Surveillance Study. Blood Advances, 2016, 1, 93-100.	5.2	7
137	Kidney function of transfused children with sickle cell anemia: Baseline data from the TWiTCH study with comparison to nonâ€transfused cohorts. American Journal of Hematology, 2017, 92, E637-E639.	4.1	7
138	Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS): study protocol for a randomized placebo-controlled trial in Ugandan children with sickle cell anemia. Trials, 2019, 20, 460.	1.6	7
139	Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. Frontiers in Physiology, 2021, 12, 636609.	2.8	7
140	Geospatial Mapping of Sickle Cell Disease in Northwest Tanzania: The Tanzania Sickle Surveillance Study (TS3). Blood, 2018, 132, 3662-3662.	1.4	7
141	A Prospective Pilot Newborn Screening and Treatment Program for Sickle Cell Anemia in the Republic of Angola. Blood, 2012, 120, 480-480.	1.4	7
142	Effects of Chronic Transfusion Therapy on MRI and MRA in Children with Sickle Cell Anemia at Risk for Primary Stroke: Baseline Imaging from the Twitch Trial. Blood, 2014, 124, 4052-4052.	1.4	7
143	Effects of Chronic Transfusion Therapy on transcranial Doppler Ultrasonography Velocities in Children with Sickle Cell Anemia at Risk for Primary Stroke: Baseline Findings from the Twitch Trial. Blood, 2014, 124, 87-87.	1.4	7
144	Cost and Reliability of Two Methods of Hemoglobin Identification for Sickle Cell Newborn Screening in the Republic of Angola. Blood, 2012, 120, 2064-2064.	1.4	7

#	Article	IF	Citations
145	Assessment of Plasmodium falciparum Artemisinin Resistance Independent of kelch13 Polymorphisms and with Escalating Malaria in Bangladesh. MBio, 2022, 13, e0344421.	4.1	7
146	Thrombophilic DNA Mutations As Independent Risk Factors for Stroke and Avascular Necrosis in Sickle Cell Anemia. Hematology, 2001, 6, 347-353.	1.5	6
147	CHEMICAL AND FUNCTIONAL ANALYSIS OF GENERIC HYDROXYUREA FORMULATIONS. Pediatric Hematology and Oncology, 2008, 25, 423-429.	0.8	6
148	Operational analysis of the national sickle cell screening programme in the Republic of Uganda. African Journal of Laboratory Medicine, 2021, 10, 1303.	0.6	6
149	Concomitant Hydroxyurea and Voxelotor: Results from the HOPE Study. Blood, 2019, 134, 1003-1003.	1.4	6
150	Effects of Hydroxyurea (HU) On Lymphocyte Subsets and the Immune Response to Pneumococcal, Measles, Mumps and Rubella Vaccination in the Pediatric Hydroxyurea Phase III Clinical Trial - BABY HUG - (ClinicalTrials.gov Identifier: NCT00006400). Blood, 2012, 120, 243-243.	1.4	6
151	Congenital Pelger-Huet anomaly in triplets. American Journal of Hematology, 1988, 27, 226-227.	4.1	5
152	Prevalence and mapping of sickle cell disease in northwestern Tanzania. Blood Advances, 2017, 1, 26-28.	5.2	5
153	Building capacity to reduce stroke in children with sickle cell anemia in the Dominican Republic: the SACRED trial. Blood Advances, 2018, 2, 50-53.	5.2	5
154	Î²â€Thalassemia pathogenic variants in a cohort of children from the East African coast. Molecular Genetics & Genomic Medicine, 2020, 8, e1294.	1.2	5
155	Novel dose escalation to predict treatment with hydroxyurea (<scp>NDEPTH</scp>): A randomized controlled trial of a doseâ€prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease. American Journal of Hematology, 2020, 95, E242-E244.	4.1	5
156	Implementation of nearâ€universal hydroxyurea uptake among children with sickle cell anemia: A singleâ€center experience. Pediatric Blood and Cancer, 2021, 68, e29008.	1.5	5
157	Microscope diagnosis of MYH9-related thrombocytopenia. Blood, 2021, 138, 1000-1000.	1.4	5
158	Glomerular Hyperfiltration and Microalbuminuria in Children with Sickle Cell Anemia.. Blood, 2009, 114, 263-263.	1.4	5
159	Genetic Predictors of Hemoglobin F Response to Hydroxyurea in Sickle Cell Anemia. Blood, 2012, 120, 241-241.	1.4	5
160	Extrahepatic Iron Deposition In Chronically Transfused Children With Sickle Cell Anemia â€“ Baseline Findings From The Twitch Trial. Blood, 2013, 122, 2238-2238.	1.4	5
161	Stroke Avoidance for Children in REpÃºblica Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia. JMIR Research Protocols, 2017, 6, e107.	1.0	5
162	Hydroxyurea Reduces the Transfusion Burden in Children with Sickle Cell Anemia: The Reach Experience. Blood, 2021, 138, 11-11.	1.4	5

#	Article	IF	Citations
163	Technological Advances in Sickle Cell Disease. Blood Cells, Molecules, and Diseases, 2017, 67, 102-103.	1.4	4
164	Effective screening leads to better outcomes in sickle cell disease. Archives of Disease in Childhood, 2018, 103, archdischild-2017-314175.	1.9	4
165	Prospective Newborn Screening for Sickle Cell Disease and Other Inherited Blood Disorders in Central Malawi. International Journal of Public Health, 2021, 66, 629338.	2.3	4
166	Increased oxygen affinity: to have and to hold. Blood, 2021, 138, 1094-1095.	1.4	4
167	Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020. PLoS ONE, 2021, 16, e0254667.	2.5	4
168	Higher Fetal Hemoglobin Following Escalation of Hydroxyurea to Maximum Tolerated Dose Provides Clinical Benefit to Children with Sickle Cell Anemia. Blood, 2014, 124, 85-85.	1.4	4
169	Variation in Serial TCD Velocity Measurements in the TCD with Transfusions Changing to Hydroxyurea (TWiTCH) Trial. Blood, 2016, 128, 1019-1019.	1.4	4
170	Reproductive equity: preserve the reserve. Blood, 2022, 139, 963-965.	1.4	4
171	Is there a little PNH in all of us?. Blood, 2005, 105, 3760-3761.	1.4	3
172	Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood and Cancer, 2020, 67, e27830.	1.5	3
173	Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation. Journal of Clinical Pharmacology, 2021, 61, 547-554.	2.0	3
174	Hydroxyurea Exposure in Lactationâ€"a Pharmacokinetics Study (HELPS). Blood, 2018, 132, 3677-3677.	1.4	3
175	Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease. Blood, 2018, 132, 505-505.	1.4	3
176	Iron Unloading By Therapeutic Phlebotomy in Previously Transfused Children with Sickle Cell Anemia: The Twitch Experience. Blood, 2016, 128, 1018-1018.	1.4	3
177	Agreement Between R2 and R2* Liver Iron Estimates Is Independent of the Type of Iron Removal Therapy: Results from the Twitch Trial. Blood, 2016, 128, 1274-1274.	1.4	3
178	Changes in Extrahepatic Iron Load in Response to Iron Chelation Versus Phlebotomy: Observations from the Twitch Trial. Blood, 2016, 128, 202-202.	1.4	3
179	Chromosomal assignment of genes involved in glycosylphosphatidylinositol anchor biosynthesis: implications for the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood, 1994, 83, 3753-7.	1.4	3
180	Principles and indications of chronic transfusion therapy for children with sickle cell disease. Clinical Advances in Hematology and Oncology, 2007, 5, 686-8.	0.3	3

#	Article	IF	Citations
181	Newborn Screening With Sickle Cell Point of Care: A Valuable Resource in Low-Income Settings. Pediatrics, 2019, 144, e20191681.	2.1	2
182	AnemoCheck-LRS: an optimized, color-based point-of-care test to identify severe anemia in limited-resource settings. BMC Medicine, 2020, 18, 337.	5.5	2
183	Newborn screening for sickle cell disease in subâ€Saharan Africa: Is the glass halfâ€full yet?. Pediatric Blood and Cancer, 2021, 68, e29137.	1.5	2
184	Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response. Blood Cells, Molecules, and Diseases, 2021, 90, 102576.	1.4	2
185	Successful Outcomes Of An Infant Sickle Cell Clinic In Luanda, Angola. Blood, 2013, 122, 2934-2934.	1.4	2
186	Cost-Effectiveness Of Neonatal Screening For Sickle Cell Disease In The Republic Of Angola. Blood, 2013, 122, 421-421.	1.4	2
187	Genetic Causes of Anemia in Malawian Children Less Than 5 Years of Age: Results from the Malawi Demographic and Health Survey. Blood, 2016, 128, 313-313.	1.4	2
188	Individualized Dosing of Hydroxyurea for Children with Sickle Cell Anemia Using a Population Pharmacokinetic-Based Model: The TREAT Study. Blood, 2016, 128, 3652-3652.	1.4	2
189	Gene Expression Profiles of Hydroxyurea Tolerant Cell Lines Identify Genetic Mechanisms That Influence Hydroxyurea Maximum Tolerated Dose. Blood, 2012, 120, 1005-1005.	1.4	2
190	Ndepth: Novel Dose Escalation to Predict Treatment with Hydroxyurea. Blood, 2015, 126, 3419-3419.	1.4	2
191	Hydroxyurea to Reduce Stroke Risk in Tanzanian Children with Sickle Cell Anemia. Blood, 2020, 136, 20-21.	1.4	2
192	US News & World Report and quality metrics: Inclusion of sickle cell disease is a matter of equity. Pediatric Blood and Cancer, 2022, 69, e29679.	1.5	2
193	New therapeutics for children with sickle cell disease: A time for celebration, caution, or both?. Pediatric Blood and Cancer, 2022, 69, .	1.5	2
194	Transient hypoplastic anemia of childhood. American Journal of Hematology, 1992, 40, 240-241.	4.1	1
195	Reply to iManage: A novel selfâ€management app for sickle cell disease. Pediatric Blood and Cancer, 2017, 64, e26358.	1.5	1
196	Modelâ€based dosing with concentration feedback as an integral part of personalized hydroxycarbamide management. British Journal of Clinical Pharmacology, 2018, 84, 1410-1412.	2.4	1
197	Pediatric Hematology. Hematology/Oncology Clinics of North America, 2019, 33, xiii-xiv.	2.2	1
198	Thereâ€™s safety in numbers. Blood, 2021, 137, 729-731.	1.4	1

#	Article	IF	Citations
199	Hemoglobin S/OARAB: Thirteen new cases and review of the literature. American Journal of Hematology, 1999, 60, 279-284.	4.1	1
200	Clinical and Laboratory Benefits of Early Initiation of Hydroxyurea with Pharmacokinetic Guided Dosing for Young Children with Sickle Cell Anemia. Blood, 2018, 132, 507-507.	1.4	1
201	Genetic Predictors of Hydroxyurea Response in Children with Sickle Cell Disease.. Blood, 2009, 114, 820-820.	1.4	1
202	Validation of Genetic Predictors for Stroke In Children with Sickle Cell Anemia. Blood, 2010, 116, 2639-2639.	1.4	1
203	Therapeutic Phlebotomy in Children with Sickle Cell Anemia, Stroke, and Iron Overload: The SWiTCH Experience. Blood, 2011, 118, 1044-1044.	1.4	1
204	Predicting Hydroxyurea Responses in Children with Sickle Cell Anemia. Blood, 2011, 118, 2131-2131.	1.4	1
205	FOXO3 Variants Are Associated With Lower Fetal Hemoglobin Levels In Children With Sickle Cell Disease. Blood, 2013, 122, 778-778.	1.4	1
206	Hydroxyurea Pharmacokinetics for Predicting Maximum Tolerated Dose in Children with Sickle Cell Anemia. Blood, 2014, 124, 2707-2707.	1.4	1
207	An Accurate and Rapid Color-Based Point-of-Care Assay for the Detection of Severe Anemia in Low Resource Settings. Blood, 2014, 124, 688-688.	1.4	1
208	Accuracy of a Rapid and Simple Point-of-Care Test for Sickle Cell Disease. Blood, 2015, 126, 2182-2182.	1.4	1
209	Pharmacokinetics and Tissue Distribution of Hydroxyurea in a Mouse Model. Blood, 2015, 126, 4579-4579.	1.4	1
210	Hydroxyurea Therapy Requires HbF Induction for Clinical Benefit in a Sickle Cell Mouse Model.. Blood, 2009, 114, 817-817.	1.4	1
211	Modulation of MicroRNA Expression In Sickle Reticulocytes Is Associated with Hydroxyurea Treatment and Fetal Hemoglobin Induction. Blood, 2010, 116, 2650-2650.	1.4	1
212	Microarray Analysis of Erythroid Gene Expression In Sickle Cell Anemia Patients Treated with Hydroxyurea.. Blood, 2010, 116, 1623-1623.	1.4	1
213	Genotoxicity Associated with Hydroxyurea Exposure in Infants with Sickle Cell Anemia: Results From the BABY-HUG Phase III Clinical Trial. Blood, 2011, 118, 8-8.	1.4	1
214	Effects of Genetic Polymorphisms on Leukocyte and Neutrophil Counts and Maximum Tolerated Dose of Hydroxyurea in Children with Sickle Cell Anemia. Blood, 2015, 126, 2165-2165.	1.4	1
215	Novel Use of Hydroxyurea in an African Region with Malaria (NOHARM): A Randomized Controlled Trial. Blood, 2017, 130, 759-759.	1.4	1
216	Realizing Effectiveness across Continents with Hydroxyurea (REACH): A Prospective Multi-National Trial of Hydroxyurea for Sickle Cell Anemia in Sub-Saharan Africa. Blood, 2018, 132, 3-3.	1.4	1

#	Article	IF	Citations
217	Hydroxyurea Therapy to Prevent Incident Stroke Among Children with Sickle Cell Anaemia in Jamaica: The Extend Trial. Blood, 2019, 134, 2269-2269.	1.4	1
218	Effect of Hydroxyurea Therapy on the Incidence of Infections in Ugandan Children with Sickle Cell Anaemia. Blood, 2021, 138, 765-765.	1.4	1
219	Genetic Variants That Influence Fetal Hemoglobin Expression from Hydroxyurea Treatment. Blood, 2020, 136, 8-9.	1.4	1
220	Optimizing Hydroxyurea Therapy with Reduced Laboratory Monitoring for Children with Sickle Cell Anemia in Sub-Saharan Africa: The Reach Experience. Blood, 2020, 136, 17-17.	1.4	1
221	Development of research capacity in sickle cell anemia in Uganda: impact of collaborations. Blood Advances, 2017, 1, 11-13.	5.2	0
222	Your tired, your poor, your huddled masses. Blood, 2019, 133, 2010-2011.	1.4	0
223	Assessment of Genotoxicity Associated with Hydroxyurea Therapy in Children with Sickle Cell Anemia.. Blood, 2009, 114, 2554-2554.	1.4	0
224	Movement of Hydroxyurea Across Cell Membranes Is Mediated by Specific Solute Carrier (SLC) Transporters.. Blood, 2009, 114, 2575-2575.	1.4	0
225	Hydroxyurea Adherence and Associated Outcomes in Medicaid Enrollees with Sickle Cell Disease.. Blood, 2009, 114, 2483-2483.	1.4	0
226	Academic Community Standards for Chronic Transfusion Therapy In Children with Sickle Cell Anemia and Abnormal Transcranial Doppler Velocities. Blood, 2010, 116, 2643-2643.	1.4	0
227	The Physiological and Clinical Effects of Interrupting a Treatment Regimen of Hydroxyurea in Young Children with Sickle Cell Anemia (SCA). Blood, 2011, 118, 2134-2134.	1.4	0
228	Identification of Genetic Modifiers Associated with Risk of Stroke in Children with Sickle Cell Anemia. Blood, 2012, 120, 3228-3228.	1.4	0
229	Organic Anion Transporting Polypeptide 1B (OATP1B) Transporters Modulate Hydroxyurea Pharmacokinetics. Blood, 2012, 120, 1008-1008.	1.4	0
230	Liver Iron Concentration By MRI In Chronically Transfused Children With Sickle Cell Anemia In The Twitch Trial. Blood, 2013, 122, 780-780.	1.4	0
231	Effect Of Genetic Modifiers Of Baseline Fetal Hemoglobin On Hydroxyurea Response In Children With Sickle Cell Disease. Blood, 2013, 122, 2216-2216.	1.4	0
232	Hydroxyurea Improves Oxygen Transport Effectiveness in Sickle Cell Anemia Patients. Blood, 2014, 124, 2716-2716.	1.4	0
233	Elevated Tricuspid Regurgitation Jet Velocity in Patients with Sickling and Non-Sickling Hemolytic Anemias: Prevalence and Correlates. Blood, 2014, 124, 4906-4906.	1.4	0
234	Brain MRI/MRA Findings after Hydroxyurea Treatment in Children with Sickle Cell Anemia. Blood, 2014, 124, 89-89.	1.4	0

#	Article	IF	Citations
235	Genetic Modifiers Influencing the Development of Albuminuria in Children with Sickle Cell Anemia. Blood, 2015, 126, 3393-3393.	1.4	0
236	Pharmacokinetics-Based Individualized Dosing Strategy to Predict Maximum Tolerated Dose of Hydroxyurea in Children with Sickle Cell Anemia. Blood, 2015, 126, 982-982.	1.4	0
237	Different Clinical Characteristics of Paroxysmal Nocturnal Hemoglobinuria in Pediatric and Adult Patients. Blood, 2015, 126, 3341-3341.	1.4	0
238	Genetic Analyses in the Uganda Sickle Surveillance Study: Modifiers of Sickle Cell Anemia and Identification of Hemoglobin Variants. Blood, 2016, 128, 2479-2479.	1.4	0
239	Using Project Echo Telementoring to Improve Sickle Cell Disease Care in the Midwest. Blood, 2016, 128, 5923-5923.	1.4	0
240	A Simple, Rapid, and Inexpensive Color-Based Hemoglobin Assay As a Robust Screening Test for Severe Anemia in Limited Resource Settings. Blood, 2018, 132, 4724-4724.	1.4	0
241	Stroke Avoidance for Children in RepÃºblica Dominicana (SACRED):a Prospective Trial to Reduce Stroke in Children with Sickle Cell Anemia. Blood, 2019, 134, 2285-2285.	1.4	0
242	Pharmacokinetics of L-Glutamine (Endari) in Pediatric and Adult Sickle Cell Disease Patients: A Phase 4, Open-Label, Single-Center Study. Blood, 2021, 138, 980-980.	1.4	0
243	Building Capacity and Assessing Stroke Risk with Transcranial Doppler Ultrasonography in Sub-Saharan Africa: The Reach Experience. Blood, 2020, 136, 17-18.	1.4	0
244	Novel Genetic Loci That Influence Fetal Hemoglobin Expression in Children with Sickle Cell Anemia. Blood, 2020, 136, 33-34.	1.4	0
245	Rapid and Automated Quantitation of Dense Red Blood Cells: A Robust Biomarker of Therapeutic Response to Early Initiation of Hydroxyurea in Young Children with Sickle Cell Anemia. Blood, 2020, 136, 16-17.	1.4	0
246	Genetic Basis of Erythrocyte Alloimmunization Among Children with Sickle Cell Anemia in the Dominican Republic. Blood, 2020, 136, 28-29.	1.4	0
247	Increased Hydroxyurea Prescribing Practices over Ten Years with Improved Clinical Outcomes in Children with Sickle Cell Anemia: A Single Center's Experience. Blood, 2020, 136, 34-34.	1.4	0